To champion a healthier world by preventing infections.
Investors
Q3: Accelerating performance validates our partnership model
-
Revenue58.4 MSEK(48.4)
-
Adjusted EBITDA20.0 MSEK(5.3)
-
Cash flow14.0 MSEK(-2.8)
Interim report Q3 2026
Bactiguard Holding AB (publ) published its interim report for the third quarter on Thursday 22 October 2026 at 07:00 CEST.
In connection with this, Bactiguard hosted an audiocast for investors, analysts, and media. You can listen to the audiocast on the right.
Annual and Sustainability Report 2025
Updated strategic and financial targets
Bactiguard Holding AB (publ.) has announced its updated strategic and financial targets following a review announced in connection with the 2024 Q3 report. The updated targets reflect a sharpened strategic focus on the license business and EBITDA profitability, a transformation delivered in 2024.
The Bactiguard Technology
The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Purpose
Vision
To be the global standard of care for preventing medical device related infections.
Mission
To be the premier partner for leading MedTech companies, joining forces to redefine healthcare and improve health worldwide.
Core values
- Respect
- Trust
- Transparency
- Performance
Bactiguard is a purpose-driven company with a strong corporate culture, firmly anchored in four core values. The values are an integral part of Bactiguard’s purpose to champion a healthier world by preventing infections and a prerequisite to achieve our targets.
Bactiguard as an investment
The ambition is to become a profitable knowledge and specialist organization which is a prerequisite to deliver on our financial, strategic and sustainability targets.
-
04Feb 2027
Year-end report 1 January – 31 December 2026
-
31Mar 2027
Annual Report 2026
-
22Apr 2027
Interim report first quarter 1 January – 31 March 2027
Investor Relations
-
Patrick Bach
CFO
+46 (0) 76 129 59 11